Journal articles on the topic 'Inc Catapult'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 37 journal articles for your research on the topic 'Inc Catapult.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Bishko, C. J. "St James's Catapult. The Life and Times of Diego Gelmírez of Santiago de Compostela. By R. A. Fletcher. Pp. xii + 341 inc. 2 maps. Oxford: Clarendon Press, 1984. £28." Journal of Ecclesiastical History 36, no. 4 (October 1985): 650–52. http://dx.doi.org/10.1017/s0022046900044067.
Full textWoyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. "Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy." Blood 138, Supplement 1 (November 5, 2021): 639. http://dx.doi.org/10.1182/blood-2021-153146.
Full textBannerji, Rajat, John N. Allan, Jon E. Arnason, Jennifer R. Brown, Ranjana H. Advani, Jeffrey A. Barnes, Stephen M. Ansell, et al. "Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)." Blood 134, Supplement_1 (November 13, 2019): 762. http://dx.doi.org/10.1182/blood-2019-122451.
Full textVartanov, Alexander R., Stacey M. Fernandes, Winnie I. Nguy, Danielle M. Brander, Svitlana Tyekucheva, Alexandra Savell, Allison P. Jacob, et al. "High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)." Blood 134, Supplement_1 (November 13, 2019): 4291. http://dx.doi.org/10.1182/blood-2019-124305.
Full textSpangler, Rhys, Timo Rantalainen, Paul Gastin, and Daniel Wundersitz. "Inertial Sensors are a Valid Tool to Detect and Consistently Quantify Jumping." International Journal of Sports Medicine 39, no. 10 (July 19, 2018): 802–8. http://dx.doi.org/10.1055/s-0044-100793.
Full textNaeem, Aishath S., Winnie I. Nguy, Svitlana Tyekucheva, Stacey M. Fernandes, Vanessa Rai, Kevin Ebata, Eliana B. Gomez, Barb J. Brandhuber, Stephen M. Rothenberg, and Jennifer R. Brown. "LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL." Blood 134, Supplement_1 (November 13, 2019): 478. http://dx.doi.org/10.1182/blood-2019-124362.
Full textMato, Anthony R., Kavita Sail, Maryam Sarraf Yazdy, Brian T. Hill, Mazyar Shadman, Beenish S. Manzoor, Hande H. Tuncer, et al. "Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies." Blood 134, Supplement_1 (November 13, 2019): 1756. http://dx.doi.org/10.1182/blood-2019-124600.
Full textShadman, Mazyar, Kavita Sail, Beenish S. Manzoor, Maryam Sarraf Yazdy, Brian T. Hill, Hande H. Tuncer, John N. Allan, et al. "Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study." Blood 134, Supplement_1 (November 13, 2019): 3048. http://dx.doi.org/10.1182/blood-2019-131401.
Full textLampson, Benjamin L., Svitlana Tyekucheva, Conner J. Shaughnessy, Annette S. Kim, and Jennifer R. Brown. "Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients." Blood 134, Supplement_1 (November 13, 2019): 1731. http://dx.doi.org/10.1182/blood-2019-127180.
Full textBrown, Jennifer R., Matthew S. Davids, Julie E. Chang, Shuo Ma, Juliana M. L. Biondo, Yong Mun, Madlaina Breuleux, and William G. Wierda. "Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)." Blood 134, Supplement_1 (November 13, 2019): 4320. http://dx.doi.org/10.1182/blood-2019-123665.
Full textLiu, Vivian M., Romain Guièze, Daniel Rosebrock, Alexis A. Jourdain, María Hernández-Sánchez, Aina Zurita Martinez, Elisa Ten Hacken, et al. "MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers." Blood 134, Supplement_1 (November 13, 2019): 1284. http://dx.doi.org/10.1182/blood-2019-131336.
Full textAllan, John N., Krish Patel, Anthony R. Mato, William G. Wierda, Javier Pinilla Ibarz, Michael Y. Choi, Susan M. O'Brien, et al. "Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies." Blood 134, Supplement_1 (November 13, 2019): 3041. http://dx.doi.org/10.1182/blood-2019-126286.
Full textMato, Anthony R., John M. Pagel, Catherine C. Coombs, Nirav N. Shah, Nicole Lamanna, Tahla Munir, Ewa Lech-Marańda, et al. "Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study." Blood 138, Supplement 1 (November 5, 2021): 391. http://dx.doi.org/10.1182/blood-2021-147599.
Full textFurman, Richard R., William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, et al. "Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study." Blood 134, Supplement_1 (November 13, 2019): 3039. http://dx.doi.org/10.1182/blood-2019-128706.
Full textZheng, Dandan, Kavita Sail, Lindsey E. Roeker, Beenish S. Manzoor, Hande H. Tuncer, John N. Allan, Chaitra S. Ujjani, et al. "Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)." Blood 136, Supplement 1 (November 5, 2020): 19–22. http://dx.doi.org/10.1182/blood-2020-134676.
Full textChahal, Amandeep Kaur, Jolene Ziyuan Lim, Jing-Wen Pan, and Pui Wah Kong. "Inter-Unit Consistency and Validity of 10-Hz GNSS Units in Straight-Line Sprint Running." Sensors 22, no. 5 (February 28, 2022): 1888. http://dx.doi.org/10.3390/s22051888.
Full textHillmen, Peter, Jennifer R. Brown, John C. Byrd, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Lugui Qiu, et al. "Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)." Blood 134, Supplement_1 (November 13, 2019): 4307. http://dx.doi.org/10.1182/blood-2019-124213.
Full textMato, Anthony R., Ian W. Flinn, John M. Pagel, Jennifer R. Brown, Chan Y. Cheah, Catherine C. Coombs, Manish R. Patel, et al. "Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor." Blood 134, Supplement_1 (November 13, 2019): 501. http://dx.doi.org/10.1182/blood-2019-127509.
Full textLancet, Jeffrey E., Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Stephen A. Strickland, Gary J. Schiller, Norbert Vey, et al. "Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study." Blood 126, no. 23 (December 3, 2015): 2560. http://dx.doi.org/10.1182/blood.v126.23.2560.2560.
Full textBachireddy, Pavan, Christina Ennis, Vinhkhang N. Nguyen, Nikolas Barkas, Sachet Shukla, Kendell Clement, Samuel Freeman, et al. "Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)." Blood 134, Supplement_1 (November 13, 2019): 516. http://dx.doi.org/10.1182/blood-2019-129520.
Full textTam, Constantine S., Ian W. Flinn, Alessandra Tedeschi, Emmanuelle Ferrant, Jennifer R. Brown, Tadeusz Robak, Paolo Ghia, et al. "Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial." Blood 136, Supplement 1 (November 5, 2020): 24–25. http://dx.doi.org/10.1182/blood-2020-134179.
Full textBrown, Jennifer R., Barbara F. Eichhorst, Paolo Ghia, Arnon P. Kater, Jianyong Li, Sudha Khurana, Mostafa Elhamy, Min Hui Wang, and John F. Seymour. "A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation." Blood 134, Supplement_1 (November 13, 2019): 4318. http://dx.doi.org/10.1182/blood-2019-123057.
Full textCrombie, Jennifer L., Svitlana Tyekucheva, Alexandra Savell, Karen Francoeur, Mark Choiniere, Josie Montegaard, Jacob D. Soumerai, et al. "A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL." Blood 134, Supplement_1 (November 13, 2019): 1763. http://dx.doi.org/10.1182/blood-2019-127343.
Full textMerryman, Reid W., Robert A. Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M. McHugh, Jennifer R. Brown, et al. "Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 22–23. http://dx.doi.org/10.1182/blood-2020-140965.
Full textBurke, Kathleen, Barrett Nuttall, Daniel L. Karl, Megan Callahan, Kerrin Mendler, Steven Criscione, Sergey Naumenko, et al. "Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing." Blood 138, Supplement 1 (November 5, 2021): 4361. http://dx.doi.org/10.1182/blood-2021-147113.
Full textDavids, Matthew S., Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai, et al. "ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia." Blood 138, Supplement 1 (November 5, 2021): 2634. http://dx.doi.org/10.1182/blood-2021-153033.
Full textLampson, Benjamin L., Svitlana Tyekucheva, Jennifer L. Crombie, Austin I. Kim, Reid W. Merryman, Jessica Lowney, Josie Montegaard, et al. "Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)." Blood 134, Supplement_1 (November 13, 2019): 32. http://dx.doi.org/10.1182/blood-2019-127506.
Full textDavids, Matthew S., Danielle M. Brander, Svitlana Tyekucheva, Chinheng Chen, James Kaminski, Josie Montegaard, Alvaro J. Alencar, et al. "Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia." Blood 138, Supplement 1 (November 5, 2021): 640. http://dx.doi.org/10.1182/blood-2021-146624.
Full textBall, William J. "Book Reviews : Beyond the Home Page Book Review Essay on Guides to Advanced Content Creation for the Web Introducing Microsoft FrontPage97. Kerry A. Lehto and W. Brett Polonsky. Redmond, WA: Microsoft Press, 1997. 384 pp., $24.99. Microsoft FrontPage97 Step by Step. Catapult Inc. Redmond, WA: Microsoft Press, 1997. 286 pp., $29.99. Web Scripting Secret Weapons. Scott Walker. Indianapolis, IN: Que Corp., 1997. 380 pp., $39.99. Special Edition Using JavaScript. Mark C. Reynolds. Indianapolis, IN: Que Corp., 1997. 831 pp., $49.99. VBScript by Example. Jerry Honeycutt. Indianapolis, IN: Que Corp., 1997. 355 pp., $34.99. Building VRML Worlds. Ed Tittle, Charlie Scott, Paul Wolfe, and Claire Sanders. Berkeley, CA: Osborne/McGraw Hill, 1997. 381 pp., $39.95." Social Science Computer Review 15, no. 4 (December 1997): 446–50. http://dx.doi.org/10.1177/089443939701500411.
Full textSeymour, John F., John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard Furman, et al. "Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)." Blood 138, Supplement 1 (November 5, 2021): 3721. http://dx.doi.org/10.1182/blood-2021-146228.
Full textTedeschi, Alessandra, Emmanuelle Ferrant, Ian W. Flinn, Constantine S. Tam, Paolo Ghia, Tadeusz Robak, Jennifer R. Brown, et al. "Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial." Blood 138, Supplement 1 (November 5, 2021): 67. http://dx.doi.org/10.1182/blood-2021-144336.
Full textBrown, Jennifer R., Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, Henry Chan, et al. "Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial." Blood 136, Supplement 1 (November 5, 2020): 11–12. http://dx.doi.org/10.1182/blood-2020-134280.
Full textTam, Constantine S., Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, et al. "SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)." Blood 138, Supplement 1 (November 5, 2021): 396. http://dx.doi.org/10.1182/blood-2021-148457.
Full textMakar, Piotr, Ana Filipa Silva, Rafael Oliveira, Marcin Janusiak, Przemysław Parus, Małgorzata Smoter, and Filipe Manuel Clemente. "Assessing the agreement between a global navigation satellite system and an optical-tracking system for measuring total, high-speed running, and sprint distances in official soccer matches." Science Progress 106, no. 3 (July 2023). http://dx.doi.org/10.1177/00368504231187501.
Full textWatts, Sophie P., Martyn J. Binnie, Paul SR Goods, Matthew M. Doyle, Jamie Hewlett, and Peter Peeling. "Garmin wearable device offers reliable alternative for on-water stroke rate and velocity measurement in rowing." Proceedings of the Institution of Mechanical Engineers, Part P: Journal of Sports Engineering and Technology, May 18, 2022, 175433712210993. http://dx.doi.org/10.1177/17543371221099364.
Full textKenawy, A., MY Khanji, M. Chirvasa, K. Fung, A. Sojoudi, JOSE M. Paiva, N. Samy, W. Farid, TS Khalil, and SE Petersen. "Application of a machine learning contouring tool for the evaluation of left ventricular strain in clinical practice." European Heart Journal - Cardiovascular Imaging 22, Supplement_1 (January 1, 2021). http://dx.doi.org/10.1093/ehjci/jeaa356.259.
Full textSexton-Finck, Larissa. "Violence Reframed: Constructing Subjugated Individuals as Agents, Not Images, through Screen Narratives." M/C Journal 23, no. 2 (May 13, 2020). http://dx.doi.org/10.5204/mcj.1623.
Full text